RJA
AERI

Raymond James & Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Raymond James & Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42,662
Closed -$683K – 4309
2021
Q2 		$683K Buy
42,662
+914
+2% +$15.7K ﹤0.01% 2852
2021
Q1 		$746K Buy
41,748
+1,126
+3% +$19.4K ﹤0.01% 2710
2020
Q4 		$549K Sell
40,622
-31
-0.1% -$375 ﹤0.01% 2746
2020
Q3 		$478K Sell
40,653
-1,587
-4% -$19.3K ﹤0.01% 2658
2020
Q2 		$623K Buy
42,240
+215
+0.5% +$3.18K ﹤0.01% 2449
2020
Q1 		$567K Buy
42,025
+7,389
+21% +$140K ﹤0.01% 2336
2019
Q4 		$837K Sell
34,636
-15,681
-31% -$325K ﹤0.01% 2381
2019
Q3 		$967K Buy
50,317
+39
+0.1% +$894 ﹤0.01% 2222
2019
Q2 		$1.49M Buy
+50,278
New +$1.94M ﹤0.01% 1973
2018
Q4 		– Sell
-17,175
Closed -$1.06M – 3738
2018
Q3 		$1.06M Sell
17,175
-8,399
-33% -$540K ﹤0.01% 2226
2018
Q2 		$1.73M Buy
25,574
+120
+0.5% +$6.71K ﹤0.01% 1853
2018
Q1 		$1.38M Sell
25,454
-31,440
-55% -$1.76M ﹤0.01% 1923
2017
Q4 		$3.4M Sell
56,894
-1,739
-3% -$105K 0.01% 1350
2017
Q3 		$2.85M Buy
58,633
+792
+1% +$43.2K 0.01% 1401
2017
Q2 		$3.04M Sell
57,841
-24,552
-30% -$1.14M 0.01% 1309
2017
Q1 		$3.74M Sell
82,393
-30,639
-27% -$1.37M 0.01% 1165
2016
Q4 		$4.28M Sell
113,032
-3,897
-3% -$147K 0.01% 1068
2016
Q3 		$4.41M Buy
116,929
+64,366
+122% +$1.42M 0.01% 1014
2016
Q2 		$925K Buy
52,563
+3,411
+7% +$55.2K ﹤0.01% 1774
2016
Q1 		$598K Sell
49,152
-3,987
-8% -$63.1K ﹤0.01% 1953
2015
Q4 		$1.29M Sell
53,139
-4,057
-7% -$94.7K ﹤0.01% 1494
2015
Q3 		$1.01M Sell
57,196
-34,934
-38% -$633K ﹤0.01% 1591
2015
Q2 		$1.63M Buy
92,130
+38,199
+71% +$700K 0.01% 1444
2015
Q1 		$1.69M Buy
+53,931
New +$1.56M 0.01% 1341
2014
Q4 		– Sell
-12,000
Closed -$248K – 2326
2014
Q3 		$248K Buy
+12,000
New +$237K ﹤0.01% 2105

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Raymond James & Associates's AERI Position: Q3 2021 in Review

Raymond James & Associates sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 42,662 shares — an estimated $683K sold.

Raymond James & Associates first reported a position in AERI in Q3 2014 and held it in 25 quarters. The position peaked at $4.41M in Q3 2016. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Raymond James & Associates reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 42,662 Aerie Pharmaceuticals shares in Q3 2021, an estimated $683K.
  • Raymond James & Associates first reported a position in Aerie Pharmaceuticals in Q3 2014 and held it in 25 quarters.
  • Raymond James & Associates's Aerie Pharmaceuticals position peaked at $4.41M in Q3 2016.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.